Revised SPC: Cresemba (isavuconazonium sulfate) – all products

SPC now warns of potential interaction between isavuconazole and protease inhibitors mediated by CYP3A4/5 inhibition; therefore careful monitoring needed for drug toxicity/lack of anti-viral effect. Peripheral oedema has been added as uncommon ADR for capsule formulation.

electronic Medicines compendium